×

Cancer Genetics to Report Fourth Quarter and Year-End 2013 Results on Wednesday, March 26, 2014

RUTHERFORD, N.J., March 21, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, announced today that it will report its results for the fourth quarter and year-end 2013 after the market close on Wednesday, March 26, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific.

Conference Call & Webcast
Wednesday, March 26, 2014 @ 4:30pm Eastern Time/1:30pm Pacific Time
Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13579135
Webcast: http://www.cancergenetics.com
Replays – Available through April 9, 2014
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 13579135

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations Michael Rice Life Science Advisors LLC 646-597-6979 Media Relations Paul Kuntz RedChip Companies, Inc. 800-733-2447, ext. 105 paul@redchip.comSource:Cancer Genetics